Menu Search
Equities

Allergy Therapeutics PLC

AGY:LSE

Allergy Therapeutics PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)5.40
  • Today's Change-0.20 / -3.57%
  • Shares traded913.44k
  • 1 Year change+280.28%
  • Beta1.9205
Data delayed at least 20 minutes, as of Nov 08 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Allergy Therapeutics PLC's revenues fell -18.11% from 72.77m to 59.59m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 13.78m to a larger loss of 43.07m.
Gross margin52.54%
Net profit margin-94.29%
Operating margin-81.83%
Return on assets-71.39%
Return on equity-155.90%
Return on investment-102.10%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at Allergy Therapeutics PLC fell by 5.67m. Cash Flow from Financing totalled 27.80m or 46.65% of revenues. In addition the company used 28.88m for operations while cash used for investing totalled 4.59m.
Cash flow per share-0.0147
Price/Cash flow per share--
Book value per share0.0056
Tangible book value per share0.0045
More ▼

Balance sheet in GBPView more

Allergy Therapeutics PLC has a Debt to Total Capital ratio of 27.13%, a higher figure than the previous year's 20.73%.
Current ratio1.40
Quick ratio0.9281
Total debt/total equity0.3722
Total debt/total capital0.2713
More ▼

Growth rates in GBP

Year on year, growth in earnings per share excluding extraordinary items dropped -200.00%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-29.59
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.